Because each and every patient deserves personnalized curative treatments.
NETRI devotes its time and creativity to discover the brain, reinvent healthcare, and improve lives.
ABOUT NETRI OUR FACILITIES OUR STRATEGIC PRIORITIES OUR R&D PROGRAMS OUR PARTNERS & CLIENTS OUR DISTINCTIONS OUR VISION & MISSION
Our vision
Disrupting neuroscience
Give patients hope

We are convinced that NETRI’s expertise can bring hope to patients with neurological diseases by inventing innovative and high-end technologies and services, that are not yet available on the market.
New and disruptive approaches can be invented, through :

the understanding
the modeling
the improvement of existing treatment, for the benefit of all patients
Our mission

NETRI can change the way neurological diseases are treated, by acting and thinking differently.

 

We are committed to

  • Increasing discoveries on the brain and neurology
  • Contributing to the invention of new, personalized, and relevant disruptive treatment approaches
  • Speeding up the market entry of these approaches
  • Alleviating the suffering of patients and their relatives
  • Ethic position on animal testing

Our strategic priorities

We believe neurological disorders need an urgent response and are therefore our top strategic investment priorities
4 pathologies
NETRI focuses on 4 major global
diseases and epidemics
  • Alzheimer’s disease,
  • Parkisnon’s disease,
  • Huntington‘s disease,
  • Pain
4 Models
Organ-on-chip devices to model neurological disorders
14 devices
Exploration of a neurological compound : structural and functional mode of action
  • Axonal growth,
  • Functional recording,
  • Growth kinetics,
  • Synaptic toxicity,
  • Vesicular transport,
Our R&D programs

We are comited to continuously investing in research programs to

  • Develop new in vitro models and demonstrate their physiological relevance: neurofluidic models of Alzheimer’s and Parkison’s diseases and their injuries, degeneration of Lewy body, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FLD), gut-brain axis and innervated epidermis
  • Develop Standard Operating Protocols (SOP) for human induced pluripotent stem cells (iPScs) and patient-derived iPSCs differentiated neurons in our neurofluidic devices
  • Develop the first in vitro differential diagnostic medical device for neurological troubles, in collaboration with Lyon’s Hospital
  • Seeking partners for joint development with pharmaceutical industrials
OUR FACILITIES
NETRI controls its entire production chain
R&D Biolabs
Production laboratory
OUR PARTNERS
ACADEMIC PARTNERS
INDUSTRY ASSOCIATIONS
BUSINESS PARTNERS
INSTITUTIONAL PARTNERS
OUR CLIENTS
OUR DISTINCTIONS